



25 February 2026

## Investor Briefing: Business Update

**Control Bionics Limited (ASX: CBL)**, an Australian leader in Electromyography (EMG) medical device technology, is pleased to announce that it will hold an investor webinar on 26 February 2026 following release of the Company's interim financial report and Appendix 4D.

Control Bionics, CEO, Jeremy Steele, and CFO, Shannon Boothroyd, will provide a short presentation which will then be followed by Q&A.

**Webinar Details:** 12:00pm Melbourne time, Thursday 26 February 2026.

**Link to register to attend the presentation:**

[CBL - Business Update Registration Link](#)

After registering, you will receive a confirmation email containing information about joining the webinar as well as dial-in details for those that wish to join by phone.

Questions can be submitted on the day or sent in advance to [sboothroyd@controlbionics.com](mailto:sboothroyd@controlbionics.com).

This ASX announcement has been approved for release by the CEO of Control Bionics Limited.

### **About Control Bionics:**

Control Bionics is a medical device company that has more than 20 years' experience in the development and use of surface Electromyography (EMG) devices.

### **About NeuroNode:**

Our core patented NeuroNode technology is a wireless wearable device that detects minute signals sent from the brain to any skeletal muscle and is captured as EMG output. This output is then sent wirelessly via the NeuroNode to a personal computer, enabling speech and other computer-controlled functions like email and texting. Our technology is integrated with eye gaze technology whereby the eye gaze enables a cursor to be moved about a computer screen, driven much like a mouse, and the NeuroNode acts as like the mouse button. Control Bionics is the only such product to harness three modalities – touch, eye and NeuroNode control – which combined yield unique benefits in terms of the ability of patients to express themselves with significantly faster speed and less fatigue.

### **About NeuroStrip:**

Control Bionics is currently commercialising its most recent advancement in its technology, the NeuroStrip. This wearable, miniaturised EMG device provides the business with the opportunity to enter new markets such as health diagnostics, sports performance and rehabilitation to name only a few potential markets.

Control Bionics operates in North America, Australia, Singapore and Japan.

For further information, please contact:

**Investors and Media:**

Jeremy Steele – CEO and Managing Director  
[jsteele@controlbionics.com](mailto:jsteele@controlbionics.com)

Brett Crowley - Company Secretary  
[brettcrowley@controlbionics.com](mailto:brettcrowley@controlbionics.com)

For further information visit the website: <https://www.controlbionics.com/>